$1.60 USD
Updated May 24 12:00am
Add GNPX to WatchlistTrade Grade Buy & Hold Grade Peer Grade Industry Rank
| Event/Time | News Detail | Start | End | Change | |||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Genprex, Inc., a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome. The company was founded in 2009 and is based in Austin, Texas.
| Current price | $1.60 |
| Prev. close | $1.58 |
| Day low | $1.58 |
| Day high | $1.64 |
| 50-day MA | $1.77 |
| 200-day MA | $1.76 |
| 52-week high | $12.24 |
| 52-week low | $0.95 |
| Volume | 2,000 |
| Avg. volume | 38,658 |
| Dividend yield | N/A |
| Market Cap | 24.96M |
| 1-mo | -11.11% |
| 3-mo | 7.38% |
| 6-mo | 31.15% |
| 1-year | -81.94% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 45.45% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
| 2015 | N/A |
| 2014 | N/A |
Loading social stream, please wait...